Related Experiment Video
Updated: May 3, 2026
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Relationship Between Elective Neck Irradiation and Severe Lymphopenia in Patients Treated With Head and Neck
T A Mickel1, D H Moon1, V Avkshtol1
1Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Introduction:
Lymphopenia is a complication of head and neck radiotherapy, but its specific drivers are not well understood. We analyzed relationships between the extent of elective nodal irradiation (ENI) and severe lymphopenia (SL, grade 4) in patients treated with chemoradiotherapy (CRT) for head and neck squamous-cell carcinoma (HNSCC).
Methods:
We included patients with new T1-4N0-3M0 HNSCC of the oropharynx, larynx, and hypopharynx who were treated with definitive CRT between 2017 and 2021 on either two prospective phase II ENI de-escalation trials (INFIELD, INRT-AIR) or with standard-of-care (SOC) CRT. We recorded absolute lymphocyte count before and up to 1-2 years after treatment. Differences in SL were compared between cohorts, and relationships between the carotid artery (CA) and cervical spine (CS) dose, SL, and locoregional progression-free, distant metastasis-free, and overall survival (LRPFS, DMFS, OS) were investigated.
Results:
A total of 169 patients from INFIELD (N = 57), INRT-AIR (N = 61), and SOC (N = 51) were included. The SL incidence increased with increasing ENI dose: 1.6%, 16% and 35% in the INRT-AIR, INFIELD and SOC cohorts, respectively (p < 0.001). On multivariate analysis, higher mean dose to the contralateral CA (OR 9.0, 95% CI 1.9-43.7) and CS (OR 5.1, 95% CI 1.04-25.2) was associated with SL. Cox regression showed independent relationships between CS dose and OS (HR 2.96, 95% CI 1.38-6.3) and DMFS (HR 2.72, 95% CI 1.34-5.51).
Conclusions:
ENI de-escalation resulted in significantly less SL, and we identified novel predictors of this toxicity. Mitigating RT-induced SL may play a role in combining RT with immunotherapy in the definitive setting.
